Strategies for Design of Non Peptide CCK1R Agonist/Antagonist Ligands

Author(s): M. Teresa Garcia-Lopez, Rosario Gonzalez-Muniz, Mercedes Martin-Martinez, Rosario Herranz

Journal Name: Current Topics in Medicinal Chemistry

Volume 7 , Issue 12 , 2007

Become EABM
Become Reviewer
Call for Editor


This review mainly covers last five year literature on CCK1R agonists and antagonists. These CCK1R ligands have been found following the two usual and complementary strategies for drug discovery: rational design based on structure activity relationships on the CCK-7 and CCK-4 peptide sequences of the endogenous ligands and random screening of diverse compounds, followed by hit optimization. The first group includes: chimeric bifunctional opioid/CCK peptides, designed as opioid agonists with balanced CCK1R/CCK2R antagonist activity for the treatment of neuropathic pain, antagonist and agonist dipeptoids, and 1,3-dioxoperhydropyrido[1,2-c]pyrimidine- and anthranilic acidbased antagonists. Among the ligands derived from random screening, a few new 1,4-benzodiazepine-, 1,5- benzodiazepine-, and five member ring heterocycle-based CCK1R ligands have been reported. Finally, taking into account the importance of receptor mapping studies for ligand optimization and future precise de novo receptor structurebased design of new selective and more effective ligands, the most significant conclusions of these studies have also been reviewed.

Keywords: CCK1R ligands, peptidomimetics, Dipeptoids, Anthranilic Acid, 1,5-benzodiazepine

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [1180 - 1194]
Pages: 15
DOI: 10.2174/156802607780960537
Price: $65

Article Metrics

PDF: 8